Elanco Animal Health (ELAN) Stock Overview
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ELAN from our risk checks.
ELAN Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Elanco Animal Health Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.85 |
| 52 Week High | US$27.72 |
| 52 Week Low | US$12.40 |
| Beta | 1.69 |
| 1 Month Change | -11.95% |
| 3 Month Change | -17.26% |
| 1 Year Change | 65.21% |
| 3 Year Change | 148.21% |
| 5 Year Change | -41.61% |
| Change since IPO | -42.08% |
Recent News & Updates
Analysis Article • May 08
Results: Elanco Animal Health Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates
Elanco Animal Health Incorporated ( NYSE:ELAN ) just released its latest first-quarter results and things are looking...
Narrative Update • May 03
ELAN: Pet And Farm Segment Execution Will Drive Fairly Valued Outlook
Analysts have made a modest downward adjustment to the fair value estimate for Elanco Animal Health, trimming it by about $0.24. They also highlighted slightly higher revenue growth and profit margin assumptions and cited recent price target increases from several firms following stronger than expected quarterly results and updated guidance.Recent updates
Analysis Article • May 08
Results: Elanco Animal Health Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates
Elanco Animal Health Incorporated ( NYSE:ELAN ) just released its latest first-quarter results and things are looking...Narrative Update • May 03
ELAN: Pet And Farm Segment Execution Will Drive Fairly Valued Outlook
Analysts have made a modest downward adjustment to the fair value estimate for Elanco Animal Health, trimming it by about $0.24. They also highlighted slightly higher revenue growth and profit margin assumptions and cited recent price target increases from several firms following stronger than expected quarterly results and updated guidance.Seeking Alpha • Apr 20
Elanco Animal Health: Relying On Innovation To Drive Growth
Summary Elanco Animal Health has demonstrated strong organic growth, driven by innovative products, with shares rebounding 80% since May. Despite accelerating sales and innovation revenues, earnings growth has lagged, and the current valuation at 23x forward earnings reflects much of the recovery. Guidance points to continued innovation-driven growth, with innovation sales expected to double by 2028 and EBITDA margins potentially reaching 21%–22.5%. I remain cautiously optimistic, maintaining a modest long position, but see no compelling reason to add at current elevated multiples. Read the full article on Seeking AlphaNarrative Update • Apr 18
ELAN: Pet Health And Farm Animal Execution Will Shape Fairly Valued Outlook
The analyst price target for Elanco Animal Health has been raised by a few dollars into the low $30s, with analysts pointing to stronger than expected recent results, improved margin expectations, and a reset future P/E assumption as key supports for the higher fair value estimate, which now stands at about $22.73. Analyst Commentary Recent Street research on Elanco Animal Health has concentrated on refining valuation assumptions after a period of stronger than expected results and updated guidance.
Narrative Update • Apr 04
ELAN: Pet And Farm Segment Momentum Will Shape 2026 Earnings Outlook
Elanco Animal Health's updated analyst price target has moved higher from about $25.92 to $28.77, reflecting analysts' response to a series of target raises following quarterly results that exceeded guidance and Street expectations, as well as broad-based strength across pet health and farm animal segments. Analyst Commentary Recent Street research around Elanco Animal Health has been active, with several firms adjusting price targets following quarterly results and updated guidance.
Narrative Update • Mar 21
ELAN: Pet Dermatology Approvals And Q4 Execution May Support Further Upside
Analysts have raised the average price target on Elanco Animal Health to $32 from about $30, citing recent earnings beats, broad-based segment strength, and updated expectations that support a higher fair value along with a materially higher future P/E assumption in their models. Analyst Commentary Recent research points to a clear shift toward more constructive views on Elanco Animal Health, with several bullish analysts raising price targets into the high $20s and low $30s and reaffirming positive ratings following recent results.Narrative Update • Mar 07
ELAN: Dermatology And Pet Health Pipeline Optimism Will Test Execution And Margins
The updated analyst price target for Elanco Animal Health moves higher, reflecting a shift in our fair value estimate from $20.20 to $22.49 as analysts respond to recent target raises and supportive commentary regarding Q4 performance, 2026 guidance, and product momentum. Analyst Commentary Street research on Elanco Animal Health in recent months has leaned constructive, with several firms lifting their price targets following Q4 results, updated 2026 guidance, and commentary on product momentum across pet health and farm animal.
New Narrative • Feb 22
Elanco Animal Health (ELAN) Unleashing the Pipeline: Can New Launches Lead the Pack?
Elanco (ELAN) is entering a critical execution phase as of late February 2026, with the stock currently trading at $24.98. Following its successful strategic pivot away from low-margin legacy products, the company is now fully centered on its high-growth "Innovation" pillar.Narrative Update • Feb 21
ELAN: New Dermatology Pipeline Optimism Will Likely Outrun Execution And Margin Progress
Analysts have lifted their average price target on Elanco Animal Health by $0.20 to about $20.20. This reflects updated assumptions around slightly higher revenue growth, modestly improved profit margins, and a lower future P/E multiple in light of recent target increases and rating changes from multiple firms.Narrative Update • Feb 07
ELAN: New Pet Health Launches And Balance Sheet Progress Will Shape Outlook
Analysts have raised their fair value estimate for Elanco Animal Health by about $1.76 to $25.92, citing higher Street price targets, recent upgrades and Overweight initiations that highlight potential benefits from new product launches, revenue growth efforts and ongoing balance sheet improvement. Analyst Commentary Recent research coverage on Elanco Animal Health has leaned constructive, with several firms lifting price targets or initiating and upgrading ratings after reviewing the company’s new product pipeline, revenue initiatives and balance sheet trajectory.Narrative Update • Jan 23
ELAN: New Product Optimism Will Likely Outrun Margin And Leverage Progress
Our analyst price target for Elanco Animal Health has been revised to US$20.00. This reflects updated assumptions for revenue growth, margin potential, and a lower future P/E multiple in light of recent analyst commentary highlighting new product driven growth and efforts to improve profitability and leverage.Narrative Update • Jan 09
ELAN: New Pet Health Launches And Margin Expansion Plans May Support Upside
Our analyst fair value estimate for Elanco Animal Health has been raised from US$18.00 to about US$29.84. This change reflects higher Street price targets in the US$24 to US$27 range and analyst expectations for stronger revenue growth, wider margins, and improved leverage supported by recent product launches.Narrative Update • Dec 22
ELAN: Margin Expansion Hurdles Will Cap Upside Despite Product Launch Momentum
We raise our fair value estimate for Elanco Animal Health to approximately $20 per share from about $14. This reflects analysts' higher price targets that emphasize accelerating revenue growth from recent product launches, meaningful margin expansion potential, and improving leverage and cash flow.Narrative Update • Dec 08
ELAN: New Product Launches And Margin Expansion Will Shape 2025 Outlook
The analyst fair value estimate for Elanco Animal Health has inched higher to approximately $24.17 from $24.08, as analysts factor in stronger revenue growth from recent product launches, improving margin prospects, and accelerating EBITDA, supported by multiple upward revisions to Street price targets in the mid $20s. Analyst Commentary Recent Street research on Elanco Animal Health has turned increasingly constructive, with a series of ratings upgrades and price target increases into the mid to high 20 dollar range.Narrative Update • Nov 24
ELAN: Margin Expansion And New Product Launches Will Shape Outlook For 2025
Elanco Animal Health's fair value estimate has risen from $21.91 to $24.08. Analysts highlight improved revenue growth prospects and expanding profit margins, which are reflected in recent upward revisions to price targets.Narrative Update • Nov 09
ELAN: Margin Expansion And Profitability Will Drive Measured Outlook For 2025
Elanco Animal Health's consensus analyst price target has increased from $21.18 to $21.91. This change reflects greater optimism among analysts about revenue growth and margin expansion prospects for the company.Narrative Update • Oct 26
Upcoming Launches And Market Developments Will Shape Earnings Expectations This Year
The average analyst price target for Elanco Animal Health has increased by $0.64 to $21.18, as analysts cite expectations for revenue and EBITDA growth based on recent diligence and market analysis. Analyst Commentary Recent Street research has highlighted a generally optimistic outlook for Elanco Animal Health, though some analysts urge caution regarding future execution and margin expansion.Narrative Update • Oct 12
Zenrelia And Credelio Quattro Launches Will Expand Market Presence But FX Headwinds May Impact Earnings
Analysts have raised their price target for Elanco Animal Health from $18 to $23, citing improved revenue prospects and expectations that profit margins could surpass previous market estimates. Analyst Commentary Bullish Takeaways Bullish analysts see potential for revenue growth to outperform current market expectations, based on recent data analysis and survey feedback.Narrative Update • Sep 28
Zenrelia And Credelio Quattro Launches Will Expand Market Presence But FX Headwinds May Impact Earnings
Elanco Animal Health’s consensus price target was raised to $19.00, reflecting improved revenue outlook, margin upside, and increased analyst confidence in its growth trajectory. Analyst Commentary Bullish analysts cite diligence suggesting revenue upside potential.Narrative Update • Sep 13
Zenrelia And Credelio Quattro Launches Will Expand Market Presence But FX Headwinds May Impact Earnings
Elanco Animal Health’s consensus price target rose marginally to $18.55, as analysts cited improving business stability, innovation-driven sales acceleration, and enhanced confidence in leadership and execution. Analyst Commentary Bullish analysts note stabilization in Elanco’s core business and improved execution, providing a stronger foundation for success.Analysis Article • Aug 20
Elanco Animal Health's (NYSE:ELAN) Profits Appear To Have Quality Issues
Following the solid earnings report from Elanco Animal Health Incorporated ( NYSE:ELAN ), the market responded by...Narrative Update • Aug 08
Rising ESG Costs And Plant-Based Diets Will Weaken Livestock Demand
Elanco Animal Health’s consensus price target has been raised to $17.45, driven by improved business stability, accelerating growth from an enhanced innovation pipeline, and increased traction of its product CQ. Analyst Commentary Improved core business stability driven by better execution, providing a firmer foundation for future product innovation.Analysis Article • Jul 21
Elanco Animal Health (NYSE:ELAN) Has A Somewhat Strained Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • May 28
Elanco Animal Health Incorporated (NYSE:ELAN) Held Back By Insufficient Growth Even After Shares Climb 39%
Elanco Animal Health Incorporated ( NYSE:ELAN ) shareholders would be excited to see that the share price has had a...Seeking Alpha • Mar 31
Elanco Animal Health: Even Cheaper, Still Not A Buy
Summary Elanco Animal Health's stock declined 26%, but despite improved financials, high debt levels and limited growth opportunities make it a cautious investment. Fiscal 2024 saw slight revenue growth and a return to profitability, but debt remains a significant concern, with a debt-equity ratio of 0.71. Management's focus on innovative products and modest revenue growth projections for 2025 indicates potential, but high debt and slow growth hinder long-term prospects. Despite reasonable valuation multiples, ELAN's high debt and uncertain growth make it a 'Hold' rather than a 'Buy' for now. Read the full article on Seeking Alpha
New Narrative • Mar 17
Zenrelia And Credelio Quattro Launches Will Expand Market Presence But FX Headwinds May Impact Earnings
Strategic divestment and product launches are enhancing financial stability by reducing debt and increasing investment capacity, aiming to improve net margins.Seeking Alpha • Jan 15
Elanco Animal Health: Building On Success
Summary Elanco Animal Health is making progress on debt repayment, new product approvals, and launches, despite a 20.5% stock decline since August 2024. The stock drop is mainly due to safety risks with the new drug Zenrelia, requiring additional education for veterinarians, which will slow its launch. ELAN's robust pipeline and strategic acquisitions position it well for future growth, despite current setbacks with Zenrelia. Compared to Zoetis, Elanco appears significantly undervalued, offering potential upside in a high-growth industry through 2032. Read the full article on Seeking AlphaSeeking Alpha • Nov 08
Elanco Animal Health: Not Expensive, But Debt Remains An Issue
Summary Elanco Animal Health's stock is not a good investment due to high debt levels, despite potential undervaluation and recent growth in dermatology market. Quarterly results showed a decline in revenue and adjusted EPS, with both major segments reporting year-over-year revenue drops. The company's growth has been driven mainly by acquisitions, leading to high debt, which limits future growth opportunities and investments. Despite potential for margin improvement and new product contributions, the high debt levels make Elanco a "Hold" rather than a "Buy". Read the full article on Seeking AlphaShareholder Returns
| ELAN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.4% | -0.1% | -0.3% |
| 1Y | 65.2% | 38.7% | 26.7% |
Return vs Industry: ELAN exceeded the US Pharmaceuticals industry which returned 36.1% over the past year.
Return vs Market: ELAN exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| ELAN volatility | |
|---|---|
| ELAN Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ELAN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ELAN's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 9,650 | Jeff Simmons | www.elanco.com |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry.
Elanco Animal Health Incorporated Fundamentals Summary
| ELAN fundamental statistics | |
|---|---|
| Market cap | US$9.89b |
| Earnings (TTM) | -US$242.00m |
| Revenue (TTM) | US$4.89b |
2.1x
P/S Ratio-43.0x
P/E RatioIs ELAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELAN income statement (TTM) | |
|---|---|
| Revenue | US$4.89b |
| Cost of Revenue | US$2.20b |
| Gross Profit | US$2.69b |
| Other Expenses | US$2.94b |
| Earnings | -US$242.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.48 |
| Gross Margin | 55.06% |
| Net Profit Margin | -4.95% |
| Debt/Equity Ratio | 62.2% |
How did ELAN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 08:20 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elanco Animal Health Incorporated is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Glen Santangelo | Barclays |
| Ardalan Arfaei | BMO Capital Markets Equity Research |